Acer Therapeutics Inc

NASDAQ:ACER   3:30:59 PM EDT
1.47
-0.06 (-3.62%)
Products

Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS

Published: 07/28/2022 12:43 GMT
Acer Therapeutics Inc (ACER) - Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for Acer-001 for Treatment of Ucds.
Acer Therapeutics Inc - FDA Designated NDA As a Class 2 Resubmission and Set a Prescription Drug User Fee Act (pdufa) Target Action Date of January 15, 2023.